Ormerod John
Known title: DirectorCIK: 0002092962
Associated companies
Transaction History
| CSTM | ▼ Sell | Open Market | 8,000 | $280K | 6/4/2026 | View on chart |
| CSTM | ▼ Sell | Open Market | 8,000 | $280K | 6/4/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Barclays initiates coverage on Constellium with Equal-Weight rating
Barclays has started covering Constellium with an Equal-Weight rating and a $28 price target. This new analyst view comes as the company prepares to report its third-quarter results on October 28, 2026. While some analysts suggest the stock could see further gains, the new target is below the current average analyst estimate of $33.67.
Barclays initiates coverage on Constellium with Equal-Weight rating. Barclays has started covering Constellium with an Equal-Weight rating and a $28 price target. This new analyst view comes as the company prepares to report its third-quarter results on October 28, 2026. While some analysts suggest the stock could see further gains, the new target is below the current average analyst estimate of $33.67.